Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720382 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 703
- Enrollment target
NCT00720382: Completed Phase 3 study, sponsored by Meda Pharmaceuticals.
NCT00720382 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 703 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00720382, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 703 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone.
Primary Outcome
Examination of head and neck (scale: None, Mild, Moderate, Severe) for Epistaxis, Mucosal Edema, Nasal Discharge, Mucosal erythema, Mucosal Bleeding, and Crusting of mucosa. Nasal irritation was rated: 0 = None, Grade 1A = focal irritation, Grade 1B = superficial mucosal erosion, Grade 2 = moderate mucosal erosion, Grade 3 = ulceration, Grade 4 = septal perforation
Interventions
- DRUG Mometasone furoate
- DRUG 0.15% azelastine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 703 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
What the finished NCT00720382 record still lists
NCT00720382 is an interventional study that assigns participants to a tested intervention. The registered 703 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Mometasone furoate is the first listed.
NCT00720382 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00720382 about?
NCT00720382 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis". The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone.
What is the current status of trial NCT00720382?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 703 participants. The study started on 2007-03. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00720382?
The interventions under investigation include: Mometasone furoate (DRUG), 0.15% azelastine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00720382?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00720382's enrollment target sits among peer trials
703 506th of 2000 higher than 1,495 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
- NCT06027996 · 702 participants · NA
Melodi Matrix™ in Breast Reconstruction
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia